This article is more than 5 years old. Information may no longer be current.
FDA warns providers, patients of increased fracture risk with proton pump inhibitors
Click Here to Manage Email Alerts
The U.S. Food and Drug Administration warned health care professionals and patients that an increased risk of hip, spine and wrist fractures has been associated with high doses or chronic use of proton pump inhibitors, medicines commonly used to reduce stomach acid.
In the May 25 announcement, FDA said it is revising the labeling for over-the-counter (OTC) and prescription proton pump inhibitors (PPI) to include new safety information about the possibly increased fracture risk. FDA officials learned about the possibly greater risk of hip, spine and wrist fractures with PPIs from a review of seven epidemiological studies that reported greater risks of fracture with using the drugs for 1 year or more.
Possible increased risk
“Epidemiological studies suggest a possible increased risk of bone fractures with the use of proton pump inhibitors for 1 year or longer, or at high doses,” stated Joyce Korvick, MD, deputy director for safety in the FDA Division of Gastroenterology Products, in an FDA press release. “Because these products are used by a great number of people, it’s important for the public to be aware of this possible increased risk and, when prescribing proton pump inhibitors, health care professionals should consider whether a lower dose or shorter duration of therapy would adequately treat the patient’s condition.”
OTC PPIs frequently used to manage heartburn include omeprazole (Prilosec OTC, Zegerid OTC) and lansoprazole (Prevacid 24 HR).
The various PPIs available by prescription include esomeprazole (Nexium), omeprazole (Prilosec, Zegerid) and rabeprazole (Aciphex), which health care professionals may prescribe to treat gastroesophageal reflux disease or GERD, stomach and small intestine ulcers, and inflammation of the esophagus.
Labeling changes
The changed Warnings and Precautions section of the drugs’ labeling will reflect findings from the epidemiological studies, according to the release.
The FDA urged health care professionals and consumers to weigh the known benefits of PPIs against the potential risks when determining if these medications are appropriate for treatment.
In the warning FDA said it plans to conduct further investigations to determine if the PPIs actually caused the increased fracture risk and analyze data from large-scale, controlled bisphosphonate trials to assess the fracture risk in women taking them with or without PPIs.
The agency said it is also working with manufacturers of these drugs to further study the situation.
- Reference:
www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213206
